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Introduction: In the fetus, a large proportion of the superior vena cava blood flow
(QSVC) comes from the brain. To provide the possibility of using this blood flow as a
representation of fetal brain circulation, we aimed to determine the fetal QSVC and its
fraction of cardiac output during the second half of physiological pregnancies.
Materials and Methods: This was a prospective longitudinal study specifically
designed for studying fetal hemodynamic development. Healthy women with singleton
low-risk pregnancies were included. Ultrasonography was performed at 4-weekly
intervals from 20+0 gestational weeks to term. Doppler velocity recordings of the
superior vena cava (SVC) and cardiac ventricular outflow tracts were used to obtain
the time-averaged maximum velocities (TAMxV). Vessel diameters were measured to
calculate their cross-sectional areas (CSA):π(diameter/2)2. Blood flow (Q) was computed
as: h∗TAMxV∗CSA, h being the spatial blood velocity profile, to obtain QSVC and cardiac
outputs. The sum of left and right ventricular cardiac outputs constituted the combined
cardiac output (CCO). Ultrasound biometry based estimated fetal weight and brain weight
were used to normalize the flow. QSVC was also expressed as the fraction (%) of CCO.
Gestational age specific percentiles were established for each blood flow parameter using
multilevel modeling.
Results: Totally, 134 of the 142 included women were eligible for the study with 575 sets
of observations. The SVC mean diameter (19–52mm), mean TAMxV (8.83–16.14 cm/s),
andQSVC (15.4–192.0ml/min) increased significantly during the second half of pregnancy
(p< 0.001) while the mean QSVC normalized by estimated fetal weight (49 ml/min/kg) and
by estimated brain weight (50 ml/min/100 g) were relatively stable. Similarly, the mean
CCO increased (156–1,776 ml/min; p < 0.001) while the normalized CCO (509 ± 13
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ml/min/kg) and QSVC as a fraction of CCO (10 ± 0.92%) did not change significantly with
gestational age.
Conclusion: We provide reference values for fetal QSVC which increases significantly
with gestation, and constitutes roughly 10% of the fetal CCO at any time during the
second half of pregnancy.
Keywords: blood flow, fetal hemodynamics, fetal brain, cerebral circulation, superior vena cava, Doppler
INTRODUCTION
Blood supply to the brain during intrauterine life is
physiologically interesting and clinically relevant. Several
adverse perinatal events are associated with abnormal cerebral
blood flow, but its direct measurement is difficult in the perinatal
period, so alternative representations have been introduced.
The brain has a well-developed autoregulation of perfusion,
and since variation in impedance is reflected in the waveform
of the middle cerebral artery (MCA) blood velocity, this
Doppler assessment has become a valuable clinical tool for
monitoring fetal well-being, identifying circulatory compromise,
predicting perinatal outcomes and guiding treatment strategies
(1). A further extension of the technique utilizes the ratio
between umbilical artery (UA) and MCA pulsatility index (PI)
to reflect stages of fetal “brain sparing” during intrauterine
hypoxemia (2, 3), although with some limitations (4). Doppler
velocimetry also determines a raised peak blood velocity in
the MCA as a sign of fetal anemia (5, 6). However useful these
components of fetal cerebral hemodynamics are, we believe that
measuring the volume of blood flow through the brain would
add an important physiological parameter to clinical diagnosis
and management.
Determining the fetal cerebral blood supply non-invasively
by measuring blood flow in the carotid and vertebral arteries
has not been feasible in human pregnancies. In the neonatal
period, the measurement of blood flow in the superior vena cava
(SVC) has turned out to be a useful alternative representation of
the cerebral circulation in clinical medicine (7). And, the same
ultrasound technique has successfully been tested out prenatally
(8). The question is, how well the SVC represents the cerebral
circulation, as it also drains venous return from the upper body.
Experimental studies in primate fetuses near term have reported
SVC blood flow to constitute 23% of the combined cardiac output
(CCO) and brain blood flow 15.7% of CCO (9). An early study
on exteriorized previable human fetuses found similarly that
roughly 25% of the CCOwas flowing in the SVC atmid-gestation,
and that the brain circulated 14% (10). Also, fetal lamb studies
report similar results with 21% of the CCO received through
the SVC, but the brain contribution is lower as sheep brain
is considerably smaller than in humans (2–3 vs. 13% of body
weight) (11, 12).
Based on this background, we assumed that SVC blood flow,
to a large extent, represents brain circulation in the human fetus
and aimed at determining fetal SVC blood flow and its fraction
of CCO during the second half of healthy pregnancies in order to
establish normative data including reference ranges.
MATERIALS AND METHODS
This prospective observational study was embedded in a larger
project investigating physiological changes in fetal cardiovascular
function during the second half of pregnancy. The study had
a longitudinal design including low-risk singleton pregnancies
for serial ultrasound scans at ∼4-weekly intervals during 20–
41 weeks of gestation. Normative data on blood flow-based
cerebroplacental ratio (Q-CPR), umbilicocerebral ratio (Q-
UCR), and SVC velocities and pulsatility index for vein from this
study population have been published previously (13, 14). Here
we address absolute and weight-indexed QSVC and its fraction of
CCO as a representation of fetal brachio-cephalic circulation.
The study took place at the University Hospital of North
Norway, Tromsø, Norway. Written information about the study
was sent to women with the appointment letter to attend
the routine second trimester ultrasound screening. During
that session, the women were assessed for eligibility and
those who consented in written, were consecutively enrolled
during February 2009 to December 2012. Inclusion criteria
were, woman’s age ≥18 years, singleton pregnancy, live fetus,
gestation ≥18 weeks and <24 weeks confirmed by ultrasound
biometry, and absence of any major congenital fetal or placental
abnormality. Women with a previous obstetric history of
preeclampsia, gestational diabetes or preterm labor before 34
weeks of gestation, and those with illness known to affect the
course and outcome of pregnancy (such as chronic hypertension,
renal disease, autoimmune disease, pre-gestational diabetes
mellitus) were excluded. Once included, none were excluded due
to complications during pregnancy.
An ultrasound examination was performed by a specialist
obstetrician with at least 3 years of fetal ultrasound scanning
experience. The same Vivid 7 Dimension ultrasound machine
(GE Vingmed Ultrasound AS, Horten, Norway) with a 4MS
(1.5–4.3 MHz) sector transducer was used for all measurements.
Fetal weight was estimated by ultrasound biometry of head,
abdomen and femur using Hadlock formula 3 (15). Fetal Brain
weight at 28–40 weeks of gestation was estimated based on an
equation proposed by Dobbing and Sands that has been validated
for the third trimester (16): Fetal brain weight (g) = (Head
circumference, cm)3/a −b/2∗(Head circumference, cm); where
the coefficients a = 100 and b = 3,000. The brains for this
validation were obtained at necropsy from 36 human fetuses
demised between 25 weeks and term gestation. These fetuses were
selected to represent normal fetuses on the basis of having normal
growth (body weight being within 1SD for the gestational age)
and no neuropathology (17).
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To measure SVC blood flow, the blood velocity waveforms
were recorded from the SVC using pulsed-wave Doppler (8)
(Figure 1A) and its inner diameter was determined using two-
dimensional B-mode ultrasound (18) (Figure 1B) as described
previously. An average value of three measurements was
used for the calculation of blood flow. To measure the
cardiac outputs, blood flow velocity waveforms were obtained
from the left and right ventricular outflow tracts and their
respective diameters were measured at the level of aortic and
pulmonary valves using the leading-edge technique (19). Left
and right ventricular outputs constituted the combined cardiac
output (CCO).
From the blood flow velocity waveforms of each blood vessel,
the time-averaged maximum velocity (TAMxV) was measured.
An average value of three cardiac cycles was recorded. An average
of three diameter measurements were used for computing
the cross-sectional areas (CSA) of the vessel. The vessel CSA
was determined as: π(diameter/2)2. Blood flow volume (Q)
of each vessel was calculated as: h∗TAMxV∗CSA, where h
represents the spatial blood velocity profile of the vessel. For
the aorta and pulmonary artery, the spatial velocity profile
was considered to be flat (h = 1) (19–21), and for the SVC,
partially blunted (h = 0.7) (8). Normalized (weight-indexed)
Q was calculated as Q/estimated fetal weight. The QSVC was
also normalized by fetal head circumference and estimated fetal
brain weight. The SVC fraction of fetal CCO was calculated
as: (QSVC/CCO)∗100.
All women continued to attend their routine antenatal care
in parallel with the study. Delivery and neonatal outcomes were
obtained from the electronic medical records.
Statistical Analyses
Data analysis was performed using IBM SPSS Statistics for
Windows, Version 24.0. (IBMCorp, Armonk, NY) andMATLAB
R2019a (Matworks, Inc. Natick, MA). Distribution of data was
checked for each variable. A Box-Cox transformation lambda
value (λ) was calculated for each response (dependent) variable,
and rounded to the nearest integer. Based on this value all the
dependent variables were transformed to achieve best possible
normal distribution, as follows: λ = 1: no transformation;
λ = 0: logarithmic transformation; λ = 0.5; square
root transformation.
The best fitting fractional polynomials were chosen from a
list of 44 regression models based on R2 value to construct
mean curves of each dependent variable in relation to gestational
age. The mean and percentiles for each gestational week
were calculated using multilevel modeling accounting for
the repeated measures design (22). The variance between
measurements within the same fetus was the first level and
the variance between participating pregnant women as the
second level. The 2.5, 5, and 10th percentiles were calculated
by subtracting 1.960 standard deviation (SD), 1.645 SD, and
1.282 SD from the mean, respectively and the 97.5, 90, and
75th percentiles by adding similar SD values, respectively.
The 95% confidence intervals were calculated for the 5, 50,
95th percentiles.
Since normal distribution of the variables was achieved
by appropriate transformation of the primary measurements
and the reference intervals were initially calculated on the
transformed scale, reverse transformations were performed
to obtain the values of gestational-age specific reference
percentiles in the primary measurement scales. Associations
between each variable and the gestational age was tested
using the mean vector for each variable from the mixed
models accounting for longitudinal design. P < 0.05 was
considered significant.
Ethics Approval
The study was approved by the Regional Committee for
Medical and Health Research Ethics –North Norway (REK Nord
105/2008) and an informed written consent was obtained from
the participants at inclusion.
RESULTS
Of the 142 pregnant women enrolled to the study, eight
were excluded due to missing data leaving 134 with 575
observations. Adequate quality images available were used
for measuring blood velocities and diameters of the SVC
(490 paired sets of recordings), and the left and right
cardiac ventricular outflow tracts (542 and 524 paired sets of
recordings, respectively), and data were entered for statistical
analysis. Demographic characteristics and pregnancy outcomes
have been reported previously (13). In brief, the median
age was 30 years (range, 19-39), 45.5% were nullipara,
4.4% developed pregnancy complications (4 preeclampsia, 1
gestational diabetes and 1 abruptio placentae), 3.7% delivered
preterm, and 12.7% were delivered by cesarean section. Mean
birthweight was 3,600 g (range, 2,252–4,636 g), 1.4% (n =
2) had a 5-minute Apgar score <7, and there was no
perinatal death.
The gestational age specific reference percentiles of SVC
mean velocity, SVC diameter, QSVC, and QSVC normalized by
estimated fetal weight, fetal head circumference, and by fetal
brain weight are presented in Tables 1–6. The SVC mean
velocity (8.83 to 16.14 cm/s), mean diameter (19 to 52mm),
QSVC (5.4 to 192.0 ml/min) and QSVC normalized by fetal
head circumference (0.87 to 5.69 ml/cm) increased (p < 0.001)
during the second half of pregnancy (Figures 2A–D). However,
the weight-indexed QSVC (mean, 49.2 ml/min/kg) remained
relatively stable ranging from 45.6 to 53.2 ml/min/kg during
20–40 weeks of pregnancy (Figure 2E). The QSVC normalized
by estimated fetal brain weight (mean, 50.42 ml/min/100 g) did
not change significantly ranging from 45.9 to 53.8 during 28–40
weeks (Figure 2F).
The reference percentiles for left and right ventricular output,
CCO and weight-indexed CCO are presented in Tables 7–10.
Reference charts fitted with 5, 50, and 95th percentiles and their
corresponding 95% CI are shown in Figures 3A–D. The mean
CCO increased from 156 ml/min at 20 weeks to 1,776 ml/min at
40 weeks (p < 0.001), whereas the weight-indexed CCO (mean,
509 (SD,13) ml/min/kg; range, 488 to 530 ml/min/kg) did not
change significantly with gestational age (p = 0.07). The QSVC as
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FIGURE 1 | Measurement of superior vena cava (SVC) blood flow: (A) Spectral pulsed-wave Doppler velocity waveforms of the fetal SVC with tracing of maxium
velocity envelope over cardiac cycles to measure time-averaged maximum velocity. S-maximum velocity during systole, D-peak velocity during diastole, and
A-minimum velocity during atrial contraction. (B) Two-dimensional B-mode ultrasound image of SVC demonstrating measurement of its inner diameter (dotted line
between two calipers) shortly above the entrance to the right atrium (RA). AAo-Ascending aorta.
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TABLE 1 | Percentiles of fetal superior vena cava mean blood velocity (cm/s) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 21 5.39 5.88 6.48 8.83 11.54 12.37 13.12
21 33 5.54 6.06 6.69 9.17 12.04 12.92 13.71
22 30 5.69 6.23 6.90 9.51 12.54 13.48 14.32
23 32 5.83 6.41 7.11 9.86 13.06 14.04 14.93
24 17 5.98 6.59 7.32 10.21 13.58 14.62 15.55
25 30 6.13 6.76 7.53 10.56 14.10 15.20 16.18
26 29 6.28 6.94 7.74 10.91 14.64 15.79 16.82
27 28 6.42 7.11 7.95 11.27 15.18 16.39 17.47
28 27 6.57 7.29 8.16 11.63 15.72 16.99 18.13
29 21 6.72 7.46 8.37 12.00 16.27 17.60 18.80
30 34 6.86 7.64 8.58 12.36 16.83 18.22 19.47
31 27 7.01 7.81 8.80 12.73 17.40 18.85 20.16
32 18 7.15 7.99 9.01 13.10 17.97 19.48 20.85
33 25 7.29 8.16 9.22 13.48 18.54 20.12 21.54
34 25 7.44 8.33 9.43 13.85 19.12 20.77 22.25
35 27 7.58 8.51 9.64 14.23 19.71 21.42 22.96
36 20 7.72 8.68 9.85 14.61 20.30 22.08 23.68
37 20 7.86 8.85 10.06 14.99 20.89 22.74 24.41
38 25 7.99 9.02 10.27 15.37 21.49 23.41 25.14
39 18 8.13 9.19 10.48 15.76 22.10 24.09 25.88
40 2 8.26 9.35 10.69 16.14 22.71 24.77 26.63
TABLE 2 | Percentiles of fetal superior vena cava diameter (cm) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 20 0.13 0.14 0.15 0.19 0.24 0.26 0.27
21 32 0.14 0.15 0.16 0.21 0.26 0.28 0.29
22 29 0.15 0.16 0.18 0.23 0.28 0.30 0.31
23 32 0.17 0.18 0.19 0.24 0.30 0.32 0.33
24 17 0.18 0.19 0.21 0.26 0.32 0.34 0.35
25 28 0.19 0.21 0.22 0.28 0.34 0.36 0.38
26 28 0.21 0.22 0.23 0.29 0.36 0.38 0.40
27 27 0.22 0.23 0.25 0.31 0.38 0.40 0.42
28 27 0.23 0.25 0.26 0.33 0.40 0.42 0.44
29 21 0.25 0.26 0.28 0.35 0.42 0.44 0.46
30 34 0.26 0.27 0.29 0.36 0.44 0.46 0.48
31 25 0.27 0.29 0.31 0.38 0.46 0.48 0.50
32 18 0.28 0.30 0.32 0.40 0.48 0.50 0.53
33 24 0.30 0.31 0.33 0.41 0.50 0.52 0.55
34 25 0.31 0.33 0.35 0.43 0.52 0.54 0.57
35 25 0.32 0.34 0.36 0.44 0.54 0.56 0.59
36 18 0.33 0.35 0.37 0.46 0.55 0.58 0.61
37 19 0.34 0.36 0.39 0.47 0.57 0.60 0.63
38 24 0.35 0.37 0.40 0.49 0.59 0.62 0.65
39 17 0.36 0.38 0.41 0.50 0.61 0.64 0.66
40 2 0.37 0.40 0.42 0.52 0.62 0.65 0.68
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TABLE 3 | Percentiles fetal superior vena cava volume blood flow (ml/min) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 20 6.79 7.75 9.02 15.42 26.38 30.70 35.03
21 32 8.22 9.37 10.90 18.59 31.70 36.88 42.04
22 29 9.88 11.26 13.09 22.26 37.86 44.01 50.14
23 32 11.81 13.44 15.61 26.49 44.93 52.18 59.42
24 17 14.02 15.95 18.51 31.31 52.98 61.48 69.96
25 28 16.53 18.80 21.80 36.79 62.07 71.99 81.86
26 28 19.38 22.02 25.52 42.95 72.27 83.74 95.17
27 27 22.57 25.64 29.68 49.82 83.61 96.81 109.94
28 27 26.12 29.65 34.30 57.42 96.10 111.19 126.20
29 21 30.04 34.07 39.39 65.76 109.77 126.91 143.94
30 34 34.33 38.91 44.95 74.83 124.58 143.93 163.13
31 25 38.98 44.15 50.96 84.62 140.50 162.19 183.71
32 17 43.97 49.78 57.42 95.08 157.44 181.61 205.57
33 24 49.30 55.76 64.28 106.15 175.31 202.07 228.58
34 25 54.91 62.08 71.50 117.76 193.96 223.40 252.54
35 25 60.78 68.67 79.03 129.81 213.24 245.41 277.24
36 17 66.85 75.47 86.79 142.19 232.94 267.89 302.43
37 19 73.06 82.42 94.72 154.76 252.85 290.56 327.82
38 24 79.33 89.45 102.71 167.37 272.72 313.16 353.07
39 17 85.60 96.45 110.67 179.85 292.28 335.37 377.86
40 2 91.78 103.35 118.49 192.04 311.26 356.87 401.83
TABLE 4 | Percentiles of weight-indexed fetal superior vena cava volume blood flow (ml/min/kg) at 20-40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 20 15.70 19.38 24.11 44.95 72.22 81.11 89.24
21 32 16.11 19.83 24.59 45.50 72.79 81.67 89.80
22 29 16.52 20.27 25.06 46.04 73.34 82.22 90.34
23 32 16.93 20.71 25.52 46.56 73.88 82.76 90.87
24 17 17.34 21.14 25.98 47.08 74.41 83.28 91.38
25 28 17.74 21.57 26.44 47.59 74.92 83.78 91.87
26 28 18.14 21.99 26.88 48.09 75.41 84.26 92.34
27 26 18.54 22.41 27.32 48.57 75.89 84.73 92.80
28 27 18.93 22.82 27.76 49.05 76.36 85.18 93.24
29 21 19.32 23.23 28.18 49.51 76.81 85.62 93.66
30 34 19.70 23.63 28.60 49.96 77.24 86.04 94.06
31 25 20.08 24.02 29.01 50.40 77.66 86.44 94.44
32 17 20.45 24.41 29.42 50.83 78.06 86.82 94.81
33 24 20.81 24.80 29.82 51.24 78.44 87.19 95.16
34 25 21.17 25.17 30.20 51.65 78.81 87.54 95.49
35 24 21.53 25.54 30.58 52.04 79.16 87.87 95.80
36 17 21.88 25.90 30.96 52.42 79.50 88.18 96.09
37 17 22.22 26.25 31.32 52.78 79.81 88.48 96.36
38 23 22.55 26.60 31.67 53.13 80.12 88.76 96.62
39 17 22.88 26.94 32.02 53.47 80.40 89.02 96.85
40 2 23.20 27.27 32.35 53.80 80.67 89.26 97.07
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TABLE 5 | Percentiles of fetal superior vena cava volume blood flow normalized by head circumference (ml/min/cm) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 20 0.39 0.44 0.51 0.87 1.49 1.74 1.98
21 32 0.44 0.50 0.58 1.00 1.70 1.97 2.25
22 29 0.50 0.57 0.66 1.13 1.92 2.23 2.54
23 32 0.57 0.65 0.75 1.28 2.16 2.51 2.86
24 17 0.64 0.73 0.85 1.44 2.43 2.82 3.21
25 28 0.73 0.82 0.96 1.61 2.72 3.15 3.58
26 28 0.81 0.92 1.07 1.80 3.03 3.51 3.99
27 26 0.91 1.03 1.20 2.01 3.36 3.89 4.42
28 27 1.01 1.15 1.33 2.23 3.72 4.30 4.88
29 21 1.12 1.28 1.47 2.46 4.10 4.74 5.38
30 34 1.24 1.41 1.63 2.71 4.50 5.20 5.89
31 25 1.37 1.55 1.79 2.97 4.93 5.69 6.44
32 17 1.50 1.70 1.96 3.24 5.37 6.19 7.01
33 24 1.64 1.86 2.14 3.53 5.83 6.72 7.60
34 25 1.79 2.02 2.33 3.83 6.30 7.26 8.20
35 24 1.94 2.19 2.52 4.14 6.79 7.81 8.83
36 17 2.10 2.36 2.72 4.45 7.29 8.38 9.46
37 18 2.26 2.54 2.92 4.77 7.80 8.96 10.10
38 22 2.42 2.73 3.13 5.10 8.31 9.53 10.75
39 17 2.58 2.91 3.34 5.43 8.81 10.11 11.39
40 2 2.75 3.10 3.55 5.75 9.32 10.68 12.03
TABLE 6 | Percentiles of fetal superior vena cava volume blood flow normalized by brain weight (ml/min/100 g) at 28–40 weeks of gestational age (GA).
Percentile









28 27 22.50 25.21 28.74 45.64 72.49 82.63 92.58
29 21 22.78 25.58 29.23 46.82 74.99 85.69 96.21
30 34 23.01 25.89 29.65 47.91 77.41 88.67 99.77
31 25 23.19 26.15 30.02 48.92 79.73 91.55 103.22
32 17 23.32 26.35 30.33 49.85 81.93 94.31 106.56
33 24 23.39 26.49 30.57 50.67 84.01 96.94 109.76
34 25 23.42 26.57 30.74 51.40 85.94 99.41 112.80
35 24 23.39 26.60 30.84 52.02 87.73 101.72 115.67
36 17 23.31 26.56 30.88 52.53 89.35 103.86 118.34
37 18 23.18 26.47 30.84 52.92 90.80 105.80 120.81
38 22 23.00 26.32 30.74 53.20 92.07 107.54 123.05
39 17 22.77 26.11 30.57 53.36 93.14 109.06 125.06
40 2 22.49 25.84 30.33 53.40 94.02 110.35 126.81
No data presented for 20–27 weeks as the formula used for brain weight estimation is not valid before 28 weeks of gestation.
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FIGURE 2 | Reference charts for fetal superior vena cava (SVC): (A) mean velocity, (B) diameter, (C) volume blood flow (QSVC), (D) weight-indexed QSVC, (E) volume
blood flow normalized by head circumference (Qsvc/HC) at 20-40 weeks of gestation, and (F) volume blood flow (QSVC) normalized by estimated fetal brain weight at
28–40 weeks of gestation. The solid red line represents the 50th percentile, the blue lines represent the 5 and 95th percentiles and the interrupted black lines
represent their respective 95% confidence limits.
the fraction of fetal CCO was 10% (SD,0.92) and hardly changed
during the second half of pregnancy (Table 11; Figure 4).
DISCUSSION
Principal Findings
The study has provided reference ranges for QSVC during
the second half of pregnancy. If fetal QSVC is accepted
as a representation of fetal cerebral blood flow, this study
demonstrates that the blood flow to the brain increases almost
13-fold from 20 to 40 weeks of gestation. On the other
hand, QSVC normalized for estimated fetal weight (mean, 49
ml/min/kg) and its fraction of fetal CCO distributed to the
brachiocephalic circulation (∼10%) remain stable signifying that
brain development and function requires a correspondingly
steady perfusion during the second half of pregnancy. This is
further supported by the fact that QSVC normalized for estimated
brain weight also remains stable (mean, 50 ml/min/100 g).
Interpretation of Results
A balanced proportional distribution of fetal cardiac output
to placenta/lower body and brain/upper body is essential for
physiological development of fetal organ systems. Distribution of
fetal cardiac output to placenta in human pregnancies has been
studied relatively well-using non-invasive Doppler technique (21,
23, 24), but similar studies quantifying the physiological changes
in blood supply to fetal brain and proportion of cardiac output
distributed to brachio-cephalic circulation are scarce.
The present study demonstrated that the gestational age
associated increase in the blood supply to the fetal brain is a
result of more than 2-fold increase in the SVC diameter and
almost a similar increase in the SVC blood flow velocity during
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TABLE 7 | Percentiles of left ventricular cardiac output (ml/min) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 21 25.68 30.07 35.56 58.62 87.43 96.63 104.98
21 34 36.34 42.01 49.04 78.25 114.24 125.67 136.02
22 30 48.43 55.48 64.20 100.09 143.90 157.75 170.28
23 35 61.77 70.32 80.85 123.92 176.16 192.62 207.49
24 20 76.20 86.33 98.80 149.56 210.79 230.04 247.42
25 31 91.55 103.37 117.89 176.78 247.56 269.77 289.81
26 29 107.66 121.26 137.93 205.40 286.25 311.58 334.43
27 30 124.40 139.85 158.78 235.22 326.64 355.24 381.04
28 27 141.62 159.00 180.27 266.06 368.51 400.54 429.42
29 21 159.18 178.55 202.25 297.75 411.66 447.26 479.35
30 38 176.95 198.37 224.57 330.10 455.89 495.19 530.61
31 28 194.80 218.33 247.10 362.95 501.01 544.13 582.99
32 21 212.62 238.29 269.69 396.14 546.81 593.88 636.30
33 27 230.28 258.14 292.23 429.50 593.13 644.24 690.32
34 27 247.68 277.77 314.58 462.90 639.77 695.04 744.86
35 30 264.72 297.05 336.62 496.17 686.58 746.10 799.75
36 24 281.29 315.89 358.26 529.20 733.37 797.22 854.79
37 19 297.31 334.19 379.37 561.83 780.00 848.26 909.81
38 28 312.69 351.86 399.86 593.94 826.29 899.04 964.65
39 18 327.34 368.80 419.63 625.41 872.11 949.40 1019.13
40 4 341.20 384.93 438.59 656.12 917.31 999.20 1073.10
TABLE 8 | Percentiles of right ventricular cardiac output (ml/min) at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 17 67.61 72.89 79.49 107.95 146.61 159.88 172.37
21 34 81.47 87.82 95.75 129.94 176.35 192.28 207.27
22 27 97.43 105.00 114.47 155.24 210.55 229.52 247.37
23 34 115.65 124.62 135.82 184.09 249.50 271.93 293.02
24 20 136.25 146.79 159.96 216.65 293.44 319.76 344.51
25 30 159.32 171.62 186.98 253.08 342.55 373.20 402.02
26 29 184.91 199.15 216.93 293.42 396.88 432.32 465.62
27 30 213.00 229.37 249.80 337.65 456.40 497.05 535.26
28 25 243.53 262.20 285.50 385.65 520.92 567.22 610.71
29 20 276.35 297.49 323.87 437.18 590.13 642.45 691.60
30 37 311.25 335.01 364.64 491.89 663.53 722.23 777.35
31 28 347.95 374.44 407.48 549.31 740.50 805.84 867.20
32 20 386.06 415.39 451.96 608.85 820.21 892.42 960.21
33 26 425.15 457.37 497.54 669.81 901.72 980.92 1055.26
34 27 464.69 499.83 543.63 731.36 983.92 1070.14 1151.05
35 30 504.13 542.15 589.55 792.60 1065.60 1158.75 1246.16
36 22 542.82 583.67 634.57 852.56 1145.43 1245.33 1339.04
37 19 580.11 623.67 677.93 910.20 1222.05 1328.37 1428.10
38 27 615.34 661.43 718.84 964.48 1294.06 1406.37 1511.71
39 18 647.83 696.24 756.52 1014.36 1360.07 1477.83 1588.26
40 4 676.94 727.40 790.24 1058.85 1418.76 1541.32 1656.21
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TABLE 9 | Percentiles of combined ventricular cardiac output (ml/min) at 20-40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 17 83.93 93.97 106.25 155.65 214.45 232.81 249.35
21 34 114.12 126.70 142.02 203.09 275.06 297.41 317.52
22 27 148.20 163.53 182.13 255.85 342.06 368.74 392.70
23 34 185.88 204.17 226.31 313.60 415.11 446.43 474.53
24 20 226.90 248.35 274.25 376.04 493.85 530.12 562.64
25 30 271.00 295.79 325.70 442.84 577.96 619.48 656.67
26 28 317.92 346.23 380.36 513.72 667.08 714.14 756.28
27 30 367.40 399.42 437.98 588.37 760.91 813.79 861.12
28 25 419.20 455.10 498.29 666.49 859.10 918.08 970.84
29 19 473.09 513.01 561.03 747.80 961.35 1026.69 1085.12
30 37 528.81 572.93 625.96 832.02 1067.34 1139.29 1203.63
31 28 586.16 634.61 692.82 918.87 1176.77 1255.58 1326.05
32 20 644.89 697.81 761.39 1008.08 1289.33 1375.25 1452.05
33 26 704.80 762.33 831.41 1099.39 1404.73 1497.98 1581.33
34 27 765.67 827.92 902.68 1192.53 1522.68 1623.48 1713.58
35 30 827.30 894.39 974.95 1287.26 1642.90 1751.47 1848.50
36 22 889.48 961.52 1048.02 1383.33 1765.11 1881.65 1985.79
37 18 952.01 1029.11 1121.68 1480.49 1889.03 2013.73 2125.18
38 26 1014.72 1096.96 1195.71 1578.52 2014.40 2147.46 2266.37
39 18 1077.41 1164.89 1269.92 1677.17 2140.95 2282.55 2409.09
40 4 1139.91 1232.69 1344.12 1776.22 2268.44 2418.74 2553.07
TABLE 10 | Percentiles of normalized (weight-indexed) combined ventricular cardiac output (ml/min/kg) at 20–40 weeks of gestational age.
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 16 341.09 366.15 397.32 530.23 707.59 767.83 824.25
21 34 340.73 365.58 396.47 528.01 703.19 762.61 818.24
22 27 340.37 365.01 395.63 525.80 698.82 757.43 812.26
23 33 340.01 364.44 394.78 523.61 694.47 752.28 806.34
24 20 339.65 363.88 393.94 521.42 690.15 747.17 800.45
25 30 339.30 363.31 393.10 519.24 685.85 742.09 794.61
26 28 338.94 362.74 392.26 517.07 681.59 737.04 788.81
27 30 338.58 362.18 391.42 514.91 677.35 732.03 783.05
28 25 338.23 361.62 390.58 512.75 673.13 727.06 777.34
29 19 337.87 361.05 389.75 510.61 668.95 722.11 771.66
30 37 337.51 360.49 388.92 508.47 664.78 717.20 766.03
31 28 337.16 359.93 388.09 506.35 660.65 712.33 760.44
32 20 336.80 359.37 387.26 504.23 656.54 707.49 754.89
33 26 336.45 358.81 386.43 502.12 652.45 702.68 749.38
34 27 336.10 358.25 385.61 500.03 648.40 697.90 743.91
35 29 335.74 357.70 384.78 497.94 644.36 693.16 738.48
36 22 335.39 357.14 383.96 495.85 640.35 688.44 733.09
37 16 335.04 356.59 383.14 493.78 636.37 683.76 727.74
38 25 334.68 356.03 382.32 491.72 632.41 679.12 722.43
39 18 334.33 355.48 381.51 489.66 628.48 674.50 717.16
40 4 333.98 354.92 380.69 487.61 624.57 669.91 711.92
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FIGURE 3 | Reference charts for fetal cardiac ventricular outputs: (A) left ventricular cardiac output (LVCO), (B) right ventricular cardiac output (RVCO), (C) combined
ventricular cardiac output (CCO), and (D) normalized (weight-indexed) CCO at 20–40 weeks of gestation. The solid red line represents the 50th percentile, the blue
lines represent the 5 and 95th percentiles and the interrupted black lines represent their respective 95% confidence limits.
20–40 weeks. However, a corresponding increase in CCO led to
a rather stable weight-indexed QSVC and weight-indexed CCO.
Fetal CCO normalized to body weight is known to be relatively
stable with reported mean values ranging between 400–550
ml/min/kg particularly depending on diameter measurement
techniques, leading edge or inner-inner diameter (19–21).
Our finding was within that range with a mean CCO of
507±12 ml/min/kg. The normalized QSVC was ∼50 ml/min/kg.
Considering that the QSVC is shown to increase with elapsing
time after birth in uncomplicated preterm babies (from an
average of 62 ml/min/kg at 5 h to 75 ml/min/kg at 12 h and
82 ml/min/kg at 24 h) (25), the value we measured in normal
fetuses seems reasonable. The brachio-cephalic fraction of CCO
represented by QSVC was ∼10% in the second half of pregnancy,
which is similar to 13% calculated from the arterial side in a
previous study performed at 11–20 weeks (23).
A study performed 50 years ago that measured organ blood
flow using radioactive microspheres in exteriorized human
fetuses during pregnancy termination by hysterotomy at 10–20
gestational weeks, reported the mean cerebral blood flow to be
25 ml/min/100 g brain tissue and the average fraction of CCO
distributed to the brain to be 14%, in 11 fetuses weighing 64–
225 g (10). However, this fraction is probably smaller considering
that the mean CCO was reported to be only 363 ml/min/kg,
which was calculated as the sum of SVC, inferior vena cava and
coronary sinus blood flow without accounting for pulmonary
venous return. Furthermore, the reliability of these values is
uncertain as these measurements were not performed under
physiological conditions. In third trimester fetuses, we found the
QSVC to be ∼50 ml/min/100 g brain weight, which remained
stable during 28–40 weeks. This is in line with the reported
value of brachio-cephalic blood flow of 60 ml/min/100g brain
weight in normotensive newborns soon after birth (26). The
human fetal brain weight is about 13% of the body weight
and this ratio is also relatively constant in the second half of
pregnancy (11). Therefore, for an average 3.6 kg term fetus with
brain weighing 468 g (13% of the body weight) the cerebral
blood flow can be expected to be 234 ml/min, which is ∼15%
of CCO (∼1,550 ml/min) at term. Considering that the QSVC
includes venous return of the whole brachio-cephalic circulation
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TABLE 11 | Percentiles of fetal superior vena cava volume blood flow as the fraction of combined ventricular cardiac output at 20–40 weeks of gestational age (GA).
Percentile
GA (weeks) n 2.5th 5th 10th 50th 90th 95th 97.5th
20 16 3.63 4.19 4.95 8.87 15.91 18.78 21.67
21 29 3.63 4.18 4.93 8.82 15.78 18.60 21.46
22 25 3.62 4.18 4.92 8.79 15.68 18.47 21.30
23 30 3.63 4.18 4.93 8.77 15.61 18.38 21.18
24 17 3.64 4.20 4.94 8.77 15.57 18.32 21.10
25 27 3.67 4.22 4.96 8.79 15.57 18.31 21.07
26 26 3.70 4.25 4.99 8.83 15.60 18.33 21.09
27 26 3.73 4.29 5.04 8.88 15.66 18.39 21.14
28 24 3.78 4.34 5.09 8.96 15.76 18.49 21.25
29 18 3.83 4.40 5.16 9.06 15.89 18.63 21.39
30 33 3.90 4.47 5.24 9.17 16.05 18.81 21.59
31 24 3.97 4.55 5.33 9.31 16.25 19.03 21.83
32 17 4.05 4.64 5.44 9.47 16.49 19.30 22.12
33 24 4.15 4.75 5.55 9.65 16.77 19.61 22.46
34 25 4.25 4.86 5.68 9.85 17.08 19.96 22.85
35 25 4.37 4.99 5.83 10.09 17.44 20.37 23.30
36 16 4.49 5.14 6.00 10.34 17.84 20.82 23.81
37 16 4.64 5.30 6.18 10.63 18.29 21.33 24.38
38 24 4.79 5.47 6.38 10.95 18.79 21.90 25.01
39 17 4.96 5.66 6.60 11.30 19.35 22.53 25.72
40 2 5.15 5.88 6.84 11.68 19.96 23.23 26.50
rather than just the brain, our finding of 10% could be an
underestimation. Moreover, as the venous return from the head,
neck and upper extremities to SVC could not be examined
separately, we were unable to determine relative contributions of
cerebral and brachiocephalic blood flow to QSVC and any change
in their proportions associated with gestational age.
The SVC blood flow is likely to be affected by several
intrinsic and extrinsic factors affecting fetal heart function, such
as the cardiac contractility and loading conditions, which also
change with gestational age. An increased right atrial pressure
could possibly reduce the QSVC, but in healthy growing fetuses,
the arterial pressure increases with gestation increasing brain
perfusion, further aided by a reducing impedance in the brain.
The increasing velocities in the SVC with gestation indicates
that a sound pressure gradient drives the blood into the atrium
equilibrating any physiological increase in atrial pressure. On
the other hand, any abnormal increase in atrial pressure would
impede flow. QSVC measurement would then be a method for
assessing such a flow reduction, e.g. in case of altered cardiac
function, as the reference ranges are available now.
Studies investigating blood flow distribution in near-term
human fetuses using phase contrast magnetic resonance imaging
(MRI) have reported equal proportions of CCO (28–29%)
distributed to both the brachio-cephalic and placental circulation
in late third trimester (27, 28). However, it is less likely,
since the placental size is bigger in comparison to the fetal
brain size (17 vs. 13% of fetal bodyweight at term), placental
vascular resistance is lower as demonstrated by cerebroplacental
impedance ratio during the second half of pregnancy (29, 30),
and placental oxygen consumption is higher (37± 12ml/min/kg)
(31) compared with fetal cerebral oxygen consumption (4 ± 1.2
ml/min/kg) (32).
Proportional distribution of CCO to the brachio-cephalic
circulation appears to be well-regulated and relatively stable
in the fetus. It does not appear to change significantly in the
second half of pregnancy as shown by our present study. The
increase in blood flow to the fetal brain with advancing gestation
is most likely the result of increased left ventricular output
due to increased pulmonary venous return. The increase in
the fraction of CCO distributed to the pulmonary circulation
seen in the third trimester (19) is possibly compensated by
the proportionate reduction in right ventricular output directed
toward the placenta, as the fraction of fetal CCO supplying the
placenta has been shown to decrease from 30 to 20% in the second
half of pregnancy (21). We evaluated the relation between QSVC
and umbilical vein blood flow (QUV) as their ratio in the same
cohort and found that the mean QSVC/QUV ratio increased from
0.40 at 20 weeks to 0.76 at 40 weeks of gestation (13).
Methodological Considerations
The QSVC measured by Doppler ultrasonography is one of
the best studied measures of neonatal cerebral blood flow in
the neonatal period, but studies in human fetuses are scarce.
The present technique of combining Doppler and 2D-imaging
was used in 2012 to determine fetal QSVC during the second
half of physiological pregnancies and assess the impact of fetal
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FIGURE 4 | Reference chart for the superior vena cava (SVC) fraction (%) of fetal combined cardiac output (CCO) distributed to the brain and upper body at 20–40
weeks of gestation. The solid red line represents the 50th percentile, the blue lines represent the 5 and 95th percentiles and the interrupted black lines represent their
respective 95% confidence limits.
respiratory movement (8). We have found the reproducibility
of fetal QSVC measurement to be acceptable, with an intra-
observer coefficient of variation of 12.7% (95% CI 11.5–13.8)
and intra-class correlation coefficient of 0.98 (95% CI 0.97–
0.98) (13). Recently, QSVC measurements have been performed
in fetuses (27, 28) using phase contrast cardiac MRI. A such
study estimated fetal QSVC normalized for estimated fetal weight
to be 137 ml/min/kg, and the SVC fraction of CCO to be 28%
during 37 weeks of gestation (28). These values are much higher
than the values obtained using Doppler ultrasonography in our
study. However, these studies were based on a very limited
number of cross-sectional observations during a small gestational
age window (median 37 weeks, range 30–39 weeks). Although
both techniques are non-invasive and have been shown to be
feasible and promising, neither of them has been experimentally
validated for the measurement of cerebral blood flow. Therefore,
none of these techniques can be considered as a standard.
However, in the fetus with physiologically high heart rate, the
MRI is likely to underestimate the maximum velocities due
to the low frame rate (20 images per cardiac cycle) compared
with modern ultrasound systems with frame rates >50 images
per cardiac cycle. Furthermore, the problems associated with
gating, loss of signal, and noise caused by maternal breathing
and fetal movements can be substantial especially in earlier
gestational ages.
Strengths and Limitations
One major strength of our study is its longitudinal design which
is appropriate for studying gestational age associated changes.
Moreover, the longitudinal design is more robust and efficient
than a cross-sectional design as it allows construction of reference
intervals with one third to half of the sample size (number
of participants) with same power and precision as compared
to a cross-sectional study (33). We had a sufficient number of
observations per gestational week to construct reliable reference
ranges, but we did not stratify our analysis by fetal sex as our
sample size was not sufficient to detect an anticipated small
difference in brain blood flow.
Limitations of volume blood flow measurements are well-
described in the literature (34). We took measures to minimize
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errors. Velocity and diameter measurements of the SVC were
performed at a defined position shortly above the entrance
to the right atrium to reduce variability. The results of our
diameter measurements are similar to that of a previously
published studies (8, 18). The left and right ventricular outlet
were measured respectively at the aortic and pulmonary valve
levels, which are clear anatomical landmarks and our cardiac
output measurements are within the range of that reported
previously by other investigators (19, 35).
Implications for Research and Clinical
Practice
QSVC, a proxy for cerebral perfusion, is one of the most
commonly used hemodynamic parameters in newborns (7),
but its clinical utility in the assessment of fetal well-being has
not been assessed. We have demonstrated the feasibility of
quantifying fetal SVC blood flow using Doppler ultrasonography,
provided normative values that could be used in future clinical
studies. Moreover, it is a relatively simple method that requires
measuring blood velocity and diameter of only a single vein. The
caliber of SVC is large enough in the second half of pregnancy
to allow diameter measurement with good axial resolution. QSVC
could be used as a surrogate measure of fetal brain blood flow as
it mostly represents cerebral venous return.
Longitudinal reference percentiles established in this study
have physiological significance, but could also be useful in
serial evaluation and surveillance of fetuses at increased risk of
perinatal complications. Low QSVC reflecting reduced cerebral
blood flow has been linked to adverse neurodevelopmental
outcomes in preterm neonates (36). In the fetus, increased QSVC
could be a sign of brain-sparing due to intrauterine hypoxemia
or increased cardiac output due to hyperdynamic circulation,
whereas a low QSVC could signal inability to maintain adequate
blood supply to brain due to cardiac failure or failed cerebral
autoregulation. Therefore, the value of QSVC in predicting
perinatal outcomes merits further investigation in clinical trials.
CONCLUSION
We provide reference values of blood flow in the fetal SVC as
a representation of cerebral circulation. It increases during the
second half of pregnancy and constitutes roughly 10% of the fetal
CCO throughout that period.
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